The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue by Marusich, JA et al.
                             Elsevier Editorial System(tm) for 
Neuropharmacology 
                                  Manuscript Draft 
 
 
Manuscript Number: NEUROPHARM-D-15-00607R1 
 
Title: The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 
6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in 
brain tissue  
 
Article Type: Research Paper 
 
Keywords: 5-(2-Aminopropyl)indole (5-IT); 6-(2-Aminopropyl)indole (6-IT); 
3,4-Methylenedioxymethamphetamine (MDMA); Locomotor activity; Monoamine 
releaser; Synthetic stimulants 
 
Corresponding Author: Dr. Julie Marusich, Ph.D. 
 
Corresponding Author's Institution: RTI International 
 
First Author: Julie Marusich, Ph.D. 
 
Order of Authors: Julie Marusich, Ph.D.; Kateland Antonazzo; Bruce 
Blough; Simon Brandt; Pierce Kavanagh; John Partilla; Michael H Baumann 
 
Abstract: In recent years, use of psychoactive synthetic stimulants has 
grown rapidly. 5-(2-Aminopropyl)indole (5-IT) is a synthetic drug 
associated with a number of fatalities, that appears to be one of the 
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assays at transporters for dopamine (DAT), norepinephrine (NET), and 
serotonin (SERT) in rat brain synaptosomes. In vivo pharmacology was 
assessed by locomotor activity and a functional observational battery 
(FOB) in mice. 5-IT and 6-IT were potent substrates at DAT, NET, and 
SERT. In contrast with the non-selective releasing properties of MDMA, 5-
IT displayed greater potency for release at DAT over SERT, while 6-IT 
displayed greater potency for release at SERT over DAT. 5-IT produced 
locomotor stimulation and typical stimulant effects in the FOB similar to 
those produced by MDMA. Conversely, 6-IT increased behaviors associated 
with 5-HT toxicity. 5-IT likely has high abuse potential, which may be 
somewhat diminished by its slow onset of in vivo effects, whereas 6-IT 
may have low abuse liability, but enhanced risk for adverse effects. 
Results indicate that subtle differences in the chemical structure of 
transporter ligands can have profound effects on biological activity. The 
potent monoamine-releasing actions of 5-IT, coupled with its known 
inhibition of MAO A, could underlie its dangerous effects when 
administered alone, and in combination with other monoaminergic drugs or 
medications. Consequently, 5-IT and related compounds may pose 





x Recreational use of synthetic stimulants has grown rapidly in recent years. 
x Structurally related novel indoles were studied in pharmacological assays.  
x 5-IT and 6-IT were potent substrates at DAT, NET, and SERT.  
x 5-IT produced typical stimulant effects, while 6-IT produced serotonin toxicity.  
x These compounds pose substantial risk for abuse or adverse effects in human users. 
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In recent years, use of psychoactive synthetic stimulants has grown rapidly. 5-(2-
Aminopropyl)indole (5-IT) is a synthetic drug associated with a number of fatalities, that appears 
to be one of the newest 3,4-methylenedioxymethamphetamine (MDMA) replacements. Here, the 
monoamine-releasing properties of 5-IT, its structural isomer 6-(2-aminopropyl)indole (6-IT), 
and MDMA were compared using in vitro release assays at transporters for dopamine (DAT), 
norepinephrine (NET), and serotonin (SERT) in rat brain synaptosomes. In vivo pharmacology 
was assessed by locomotor activity and a functional observational battery (FOB) in mice. 5-IT 
and 6-IT were potent substrates at DAT, NET, and SERT. In contrast with the non-selective 
releasing properties of MDMA, 5-IT displayed greater potency for release at DAT over SERT, 
while 6-IT displayed greater potency for release at SERT over DAT. 5-IT produced locomotor 
stimulation and typical stimulant effects in the FOB similar to those produced by MDMA. 
Conversely, 6-IT increased behaviors associated with 5-HT toxicity. 5-IT likely has high abuse 
potential, which may be somewhat diminished by its slow onset of in vivo effects, whereas 6-IT 
may have low abuse liability, but enhanced risk for adverse effects. Results indicate that subtle 
differences in the chemical structure of transporter ligands can have profound effects on 
biological activity. The potent monoamine-releasing actions of 5-IT, coupled with its known 
inhibition of MAO A, could underlie its dangerous effects when administered alone, and in 
combination with other monoaminergic drugs or medications. Consequently, 5-IT and related 
compounds may pose substantial risk for abuse and serious adverse effects in human users. 
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In recent years, the non-medical use of products containing psychoactive synthetic 
stimulants has grown rapidly (Baumann et al., 2013a, 2014; EMCDDA, 2014; UNODC, 2014). 
A range of stimulant classes has appeared in the recreational drug marketplace, including 
synthetic cathinones, piperazines, and phenethylamines (EMCDDA, 2013b; Hill and Thomas, 
2011; Rosenbaum et al., 2012; Shanks et al., 2012). Many of the newer synthetic stimulants have 
been marketed as substitutes for 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”) 
including piperazines such as m-chlorophenylpiperazine and benzylpiperazine (BZP), and 
various synthetic cathinones (Bossong et al., 2010; Brunt et al., 2011, 2012; EMCDDA, 2013b; 
German et al., 2014). High doses or chronic use of synthetic stimulants can produce adverse 
effects including agitation, delusions, violent behaviors, cardiovascular stimulation, 
hyperthermia, organ damage, and even death (EMCDDA, 2014; Miotto et al., 2013; Rosenbaum 
et al., 2012). More than 200 new psychoactive substances have been identified in Europe and the 
United States, with new compounds discovered weekly (Iversen et al., 2014). In 2014 alone, 31 
new synthetic stimulants were reported in Europe and added to the growing list monitored by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (EMCDDA, 2015). 
Synthetic stimulants produce effects that are similar to those of prototypical stimulants 
like amphetamine and cocaine. BZP and synthetic cathinones from the methcathinone structural 
class induce the transporter-mediated release of dopamine (DA), norepinephrine (NE), and 
serotonin (5-HT), similar to the actions of methamphetamine and MDMA. By comparison, 
synthetic cathinones from the pyrovalerone structural class block transporter-mediated uptake of 
DA, NE, and 5-HT, similar to the actions of cocaine (Baumann et al., 2004, 2012, 2013b; 




Eshleman et al., 2013; Marusich et al., 2014; Simmler et al., 2013). Behavioral studies in rodents 
have shown that BZP and synthetic cathinones increase locomotor activity and are self-
administered, indicating a propensity for abuse and dependence (Aarde et al., 2013a, 2013b; 
2015; Creehan et al., 2015; Fantegrossi et al., 2005, 2008, 2013; López-Arnau et al., 2013; 
Marusich et al., 2012, 2014; Watterson et al., 2012, 2014; Yarosh et al., 2007). 
5-(2-Aminopropyl)indole (5-API or 5-IT) is a new synthetic compound that emerged in 
2012 (EMCDDA, 2013a) and gained attention due to its intoxicating and life-threatening adverse 
effects (Coppola and Mondola, 2013; EMCDDA, 2014). Specifically, a cluster of fifteen 
fatalities associated with the misuse of 5-IT was reported in Sweden in 2012 (Seetohul and 
Pounder, 2013). Forensic and pathological investigation of these deaths revealed that a majority 
involved the presence of 5-IT in combination with other drugs of abuse or prescribed 
medications, whereas only two cases involved 5-IT alone. Reports of non-fatal intoxications with 
5-IT are consistent with a sympathomimetic toxidrome similar to the effects of prototypic 
stimulant drugs (Bäckberg et al., 2014; EMCDDA, 2014; Seetohul and Pounder 2013). 5-IT, 
originally synthesized as a stimulant in the 1960s (Hofmann and Troxler 1963; Troxler et al. 
1968), now joins the list of psychoactive substances being diverted and sold for recreational 
purposes, and may to be one of the newest MDMA replacements (EMCDDA, 2013a, 2014; 
Seetohul and Pounder, 2013). 5-IT is sold as “research chemicals,” “benzo fury,” and “ecstasy” 
indicating that it is used for both stimulant and MDMA-like entactogenic effects (Bäckberg et 
al., 2014; EMCDDA, 2013a, 2014; Seetohul and Pounder, 2013).  
Only a few scientific articles (Banks et al., 2014; Herraiz and Brandt, 2014), reports from 




the EMCDDA (EMCDDA, 2014), and anecdotal reports from online drug user fora 
(http://www.bluelight.org/vb/threads/616728-The-Big-amp-Dandy-5-IT-5-API-Thread) are 
available with regard to the pharmacology of 5-IT or its structural isomer 6-(2-
aminopropyl)indole (6-API or 6-IT). 5-IT and 6-IT are synthetic indoles, and positional isomers 
of α-methyltryptamine (AMT), with structural similarity to MDMA (see Figure 1). Importantly, 
5-IT and 6-IT contain the substructure of α-methylphenethylamine (i.e., amphetamine), 
suggesting the compounds may have stimulant or hallucinogenic properties (EMCDDA, 2014; 
Glennon, 2014; Rothman and Baumann, 2003). Older research shows that 6-IT is more potent 
than 5-IT with respect to antagonizing the pro-convulsant effects of reserpine, and inhibiting the 
activity of monoamine oxidase (Cerletti et al., 1968). More recent studies confirm that 5-IT acts 
as a selective, reversible and competitive inhibitor of monoamine oxidase A (MAO A) (Herraiz 
and Brandt, 2014), and 6-IT was shown to evoke release of DA, NE and 5-HT (Banks et al., 
2014). Here, we compared the monoamine-releasing properties of 5-IT, 6-IT, and MDMA using 
in vitro release assays for DA transporters (DAT), NE transporters (NET) and 5-HT transporters 
(SERT) in rat brain synaptosomes (Baumann et al., 2012, 2013b). The in vivo pharmacology of 
these same compounds was assessed by measuring locomotor activity and effects in a functional 
observational battery (FOB) in mice (Marusich et al., 2012, 2014).  
2.0 Methods and Materials 
2.1 Subjects      
Adult male Sprague-Dawley rats (Charles River, Wilmington, MA, USA) weighing 300-
400 g (total n=28) were housed three per cage. Adult male ICR mice (Harlan, Frederick, MD, 




USA) weighing 30-55 g (total n= 104) were housed individually. Animals were housed in 
polycarbonate cages with hardwood bedding. All animals were drug and test naïve, and were 
housed in temperature-controlled conditions (20-24oC) with a 12 h standard light-dark cycle. 
Animals had ad libitum access to food and water in their home cages at all times. Rat 
experiments were approved by the Institutional Animal Care and Use Committee at NIDA IRP, 
while mouse experiments were approved by the Institutional Animal Care and Use Committee at 
Mispro Biotech. All research was conducted as humanely as possible, and followed the 
principles of laboratory animal care (National Research Council, 2011). The authors consulted 
the ARRIVE guidelines for reporting experiments involving animals, and all efforts were made 
to minimize animal suffering, reduce the number of animals used, and utilize alternatives to in 
vivo techniques, if available. 
2.2 Drugs 
Racemic 5-(2-Aminopropyl)indole (5-IT) and 6-(2-Aminopropyl)indole (6-IT) were 
synthesized and characterized following established procedures (Elliott et al. 2013; Scott et al. 
2014) and were > 97% pure. Racemic 3,4-methylenedioxy-N-methylamphetamine HCl (MDMA) 
was purchased from Cayman Chemical (Ann Arbor, MI, USA). For in vitro assays, 10 mM stock 
solutions of 5-IT, 6-IT, and MDMA were prepared in DMSO and frozen. Drug dilutions were 
prepared in assay buffer using aliquots of stock solutions. For in vivo studies, 5-IT and 6-IT were 
suspended in a vehicle of 7.8 % tween 80 N.F. (VWR, Radnor, PA) and 92.2% sterile saline USP 
(Butler Schein, Dublin, OH). MDMA was dissolved in sterile saline. Doses are expressed as 
mg/kg of the salt, and were administered at a volume of 10 ml/kg in mice. Sterile saline (100%) 




and 7.8 % tween 80 + 92.2% sterile saline were used as comparisons for all drugs for in vivo 
studies.  
2.3 In Vitro Transporter Release Assays   
Rats were euthanized by CO2 narcosis, and brains were processed to yield synaptosomes 
as previously described (Baumann et al., 2013b; Rothman et al., 2003). Synaptosomes were 
prepared from rat striatum for the DAT assays, whereas synaptosomes were prepared from whole 
brain minus striatum and cerebellum for the NET and SERT assays. For release assay 
procedures, 9 nM [3H]1-methyl-4-phenylpyridinium ([3H]MPP+) was used as the radiolabeled 
substrate for DAT and NET, while 5 nM [3H]serotonin was used as a substrate for SERT. All 
buffers used in the release assay methods contained 1 µM reserpine to block vesicular uptake of 
substrates. The selectivity of release assays was optimized for a single transporter by including 
unlabeled blockers to prevent the uptake of [3H]MPP+ or [3H]serotonin by competing 
transporters. Synaptosomes were preloaded with radiolabeled substrate in Krebs-phosphate 
buffer for 1 h (steady state). Release assays were initiated by adding 850 µl of preloaded 
synaptosomes to 150 µl of test drug; incubations were allowed to proceed for 30 min for DAT 
and NET assays, or 5 min for SERT assays. Release was terminated by vacuum filtration and 
retained radioactivity was quantified by liquid scintillation counting.   
2.4 Apparatus for Behavioral Testing 
Mouse locomotor activity was assessed in clear Plexiglass open field activity chambers 
measuring 47x25.5x22 cm. San Diego Instruments Photobeam Activity System software (model 
2325-0223, San Diego, CA, USA) was used to calculate beam breaks. Each chamber contained 




two 4x8 beam infrared arrays that monitored horizontal movement. The FOB was conducted 
during handling, and in a clear Plexiglas open field measuring 47x25.5x22 cm.  
2.5 Locomotor Activity and FOB 
Mice were randomly assigned to receive a single dose of a particular drug, saline vehicle, 
or tween 80 vehicle (n=8 per group), and the same cohort of mice was used for all behavioral 
assessments. Locomotor activity was quantified by an automated system which provides a 
general measure of movement in the horizontal plane across time. Locomotor activity tests were 
conducted during week 1. The FOB consisted of observations by a trained technician and was 
conducted during week 2. In total, each mouse was given 2 administrations of drug or vehicle, 
with a minimum 6-day wash out between each administration. All compounds were administered 
intraperitoneally (i.p.), and doses were chosen based on in vitro research from the present study.  
For initial locomotor assessments (week 1), mice received their assigned drug dose and 
immediately thereafter were placed individually into locomotor activity chambers for a 90-min 
test, conducted by a technician who was blind to treatment. Doses examined were saline vehicle, 
tween vehicle, 3.0-30.0 mg/kg MDMA, and 1.0-10.0 mg/kg 5-IT and 6-IT.  
An FOB (week 2), modified from a procedure commonly used by the Environmental 
Protection Agency (U.S. Environmental Protection Agency, 1998a, 1998b), was used to classify 
observable effects of the drugs, as determined 20 min post-injection. This assay allowed for 
assessment of a wide range of drug effects, and provided an overall behavioral profile for each 
compound, with an emphasis on detection of potential safety concerns. All measures were scored 
using an ordinal scale, with 1 = normal/no drug effect, 2 = minor-moderate drug effect, and 3 = 




major drug effect.	Methods were similar to those used in our previous studies (Marusich et al., 
2012; 2014). Doses examined were 3.0-30.0 mg/kg MDMA, 3.0-30.0 mg/kg 5-IT, 1.0-5.6 mg/kg 
6-IT, saline vehicle, and tween vehicle (n=8 for all doses except tween vehicle n=16 and 5.6 
mg/kg 6-IT n=7). FOBs were scored by a trained technician who was blind to treatment. 
Dependent measures included ataxia, bizarre behavior (e.g. jumping, rearing while facing away 
from wall), circular ambulations, convulsions, ejaculation, exploration (e.g. excessive sniffing or 
reorienting of the head), flattened body posture, forepaw treading, grooming, hind limb splay, 
hyperactivity, hypoactivity, muscle relaxation, piloerection, retropulsion, salivation, self-injury, 
stereotyped biting, stereotyped head circling, stereotyped head weaving, stereotyped licking, 
stimulation (e.g. increased heart rate, tense body), Straub tail, and tremor. 	
2.6 Data Analysis 
For in vitro release assays, statistical analyses were carried out using GraphPad Prism (v. 
5.0; GraphPad Scientific, San Diego, CA, USA). EC50 values for stimulation of release were 
calculated based on non-linear regression analysis. The EC50 value for release was used as a 
measure of substrate potency because previous findings have shown that transporter-mediated 
release of the [3H]transmitter is directly coupled to the movement of substrate drug molecules 
through the channel of the transporter (Reith et al., 2015; Sitte and Freissmuth, 2015).  For in 
vivo assays, statistical analyses were conducted using NCSS (2004; Number Cruncher Statistical 
Systems, Kaysville, Utah, USA). To facilitate comparison, data from the tween 80 vehicle group 
was included in graphs and analyses for both 5-IT and 6-IT, and data from the saline vehicle 
group was included in graphs and analyses for MDMA. Locomotor activity was expressed as 




total beam breaks per 10-min bin. Mixed model analysis of variance (ANOVA) was used to 
analyze dose effect and time course locomotor data, with time as the within-subject factor and 
dose as the between-subject factor. All tests were considered significant at p<0.05. 
FOB data were analyzed with Kruskal–Wallis one-way ANOVA by ranks for each 
dependent measure, corrected for ties. No dose of any drug produced convulsions, ejaculation, 
muscle relaxation, self-injury, or stereotyped biting; therefore, these measures were not analyzed. 
Measures were grouped into four domains, and the alpha level was controlled within each 
domain: CNS activity (α=0.0125; exploration, grooming, hyperactivity, hypoactivity), CNS 
excitability (α=0.0056; bizarre behavior, circular ambulations, retropulsion, stereotyped head 
circling, stereotyped head weaving, stereotyped licking, stimulation, Straub tail, tremor), 
autonomic effects (α=0.025; piloerection, salivation), and muscle tone/equilibrium (α=0.0125; 
ataxia, flattened body posture, forepaw treading, hindlimb splay) (Bowen et al., 1996). When 
ANOVAs revealed significant main effects or interactions, Tukey’s post hoc test was used to 
determine differences between group means.  
3.0 Results 
3.1 In Vitro Transporter Assays 
Values for the potency (i.e., EC50) of test drugs to stimulate release at DAT, NET and 
SERT are summarized in Table 1, with data for amphetamine provided as a comparison, while 
dose-response curves for stimulation of release activity are depicted in Figure 2. Amphetamine 
was previously shown to be a potent and selective releaser of [3H]MPP+ at DAT and NET 
(Baumann et al., 2013b), whereas MDMA was a non-selective releaser at DAT, NET and SERT. 




5-IT was more potent at releasing [3H]MPP+ via DAT when compared to its effects at SERT 
(Fig. 2), with a DAT/SERT ratio indicating 8-fold selectivity for DAT-mediated release. By 
contrast, 6-IT was more potent at releasing via SERT when compared to its effects at DAT (Fig. 
2), with a DAT/SERT ratio indicating a 10-fold selectivity for SERT-mediated release. It is 
noteworthy that 5-IT was more potent than MDMA as a DAT substrate, whereas 6-IT was more 
potent than MDMA as a SERT substrate. Finally, all of the test drugs were capable of full 
efficacy releasing activity.  
3.2 Locomotor Dose Response and Time Course 
Figures 3 and 4 show the effects of test compounds on locomotor activity. As depicted in 
Figure 3, MDMA and 5-IT produced dose dependent increases in beam breaks [MDMA:F(3, 
32)=23.95, p<0.001; 5-IT:F(3, 32)=21.04, p<0.001]. All compounds showed an effect of bin 
[MDMA:F(8, 224)=31.14, p<0.001; 5-IT:F(8, 224)=9.10, p<0.001; 6-IT:F(8, 280)=42.58, 
p<0.001] and an interaction between dose and bin [MDMA:F(8, 224)=3.54, p<0.001; 5-IT:F(8, 
224)=8.36, p<0.001; 6-IT:F(8, 280)=2.24, p<0.001] (Fig. 4). For MDMA and 5-IT, the dose by 
time interaction was dose dependent. Higher doses increased beam breaks for a greater number 
of bins compared to lower doses. Similarly, higher doses of MDMA showed less attenuation 
across the session. Unlike many of the doses studied here, 10.0 mg/kg 5-IT produced a slow 
increase in beam breaks during much of the session with a significant increase in beam breaks 
during 60-80 min post-injection compared to the first 10 min bin. Only 1.0 mg/kg 5-IT showed 
attenuation in beam breaks over time. 6-IT did not produce a significant difference in beam 
breaks compared to tween vehicle; however, all doses produced some attenuation in beam breaks 




over time (Fig. 4). 
Doses of 5.6-10.0 mg/kg 6-IT led to adverse effects indicative of 5-HT toxicity including 
salivation, tremor, hind limb splay, Straub tail, and flattened body posture that were noted after 
the locomotor session or the following day. One mouse administered 5.6 mg/kg and two mice 
administered 10.0 mg/kg 6-IT were euthanized due to the severity of these effects. Their 
locomotor data were included in graphs and analyses due to the similarity to data from other 
subjects given the same doses. 
3.3 Functional Observational Battery 
Results of significant drug effects for the FOB are displayed in Table 2 along with data 
for methamphetamine from a previous study for comparison (Marusich et al., 2012). Within the 
CNS activity domain, all compounds produced significant increases in exploration compared to 
vehicle [MDMA: H(3)=25.76, p<0.0125; 5-IT:H(3)=11.83, p<0.0125; 6-IT:H(3)=12.01, 
p<0.0125] . MDMA also increased hyperactivity [H(3)=23.41, p<0.0125]. 
For the CNS excitability domain, MDMA increased circular ambulations [H(3)=18.02, 
p<0.0056]. MDMA [H(3)=24.93, p<0.0056] and 5-IT [H(3)=13.71, p<0.0056] elevated 
stereotyped head weaving. 5-IT also increased stereotyped head circling [H(3)=13.62, 
p<0.0056]. Finally, MDMA elevated stimulation [H(3)=22.93, p<0.0056]. 
In the autonomic effects domain, MDMA [H(3)=19.20, p<0.025], 5-IT [H(3)=13.93, 
p<0.025], 6-IT [H(3)=16.98, p<0.025] increased piloerection compared to vehicle. Furthermore, 
MDMA increase salivation [H(3)=21.26, p<0.025]. For muscle tone/equilibrium effects, MDMA 
elevated flattened body posture [H(3)=15.16, p<0.0125], and MDMA [H(3)=16.65, p<0.0125] 




and 5-IT [H(3)=17.59, p<0.0125] increased forepaw treading.  
4.0 Discussion 
The present study demonstrates that 5-IT and 6-IT are potent substrates at DAT, NET, 
and SERT, thereby causing non-exocytotic transmitter release by reversing the normal direction 
of transporter flux (Baumann et al., 2013a; Glennon, 2014). Despite their close structural 
similarities, 5-IT displays preference for releasing activity at DAT over SERT, while 6-IT 
displays preference for SERT over DAT. Both drugs have similar potency at NET. Our data for 
6-IT are consistent with the findings of Banks et al. (2014) who showed the drug (i.e., PAL-571) 
is a monoamine releasing agent with a preference for SERT over DAT. Blough et al. (2014) 
demonstrated that AMT, a structural isomer of 5-IT and 6-IT (see Figure 1), is a non-selective 
transporter substrate and a potent agonist at 5-HT2 receptor subtypes. The effects of 5-IT and 6-
IT at various monoamine receptor subtypes are not known, and therefore warrant further study.  
The differential releasing potencies of 5-IT and 6-IT at DAT and SERT contrast with the 
similar releasing potencies of MDMA at all three transporters. Importantly, 5-IT is more potent 
than MDMA at DAT whereas 6-IT is more potent than MDMA at SERT. Our results indicate 
that 5-IT and 6-IT are mechanistically similar to MDMA, BZP, and the synthetic cathinones 
mephedrone and methylone (Baumann et al., 2004, 2012). Conversely, our test compounds are 
mechanistically distinct from synthetic cathinones in the pyrovalerone structural class including 
3,4-methylenedioxypyrovalerone (MDPV), and the more recent pyrrolidinophenones (e.g., α-
PVP), which exert their effects by blocking the reuptake of catecholamine transporters 
(Baumann et al., 2013b; Marusich et al., 2014). 




The potency and selectivity of 5-IT and 6-IT for monoamine transporters were predictive 
of their in vivo effects. For example, the high DAT potency for 5-IT correlated with increases in 
locomotor activity, similar to what has been found for a variety of new psychoactive stimulants 
(Baumann et al., 2004, 2012, 2013b; Marusich et al., 2012, 2014; Yarosh et al., 2007). 5-IT also 
produced typical stimulant effects in the FOB similar to those produced by MDMA and 
methamphetamine (Marusich et al., 2012). In contrast, the high SERT potency for 6-IT 
correlated with behaviors associated with 5-HT toxicity observed following the locomotor 
session (i.e., after 90 min), but not increased locomotor activity during the session (Green et al., 
2003; Ma et al., 2008). Salivation, tremor, hind limb splay, Straub tail, and flattened body 
posture were noted after the locomotor session or the following day. Surprisingly, 6-IT only 
increased one 5-HT-associated sign in the FOB at 20 min post-injection, piloerection. The time 
points at which these serotonergic behaviors occurred indicate that the 20 minute pretreatment 
time for FOB evaluation was too early for capturing the peak effects of 6-IT, which appears to 
have a slow onset and persistent effects in vivo. It is tempting to speculate that combined effects 
of transporter-mediated release and MAO inhibition may contribute to the sustained effects of 6-
IT. Further studies should determine the precise underpinnings of the adverse effects of 6-IT in 
rodent models. 
It is well established that monoamine releasers with high selectivity for DAT/NET versus 
SERT function as strong positive reinforcers in animal models, and typically have high abuse 
liability in humans (Banks et al., 2014; Negus et al., 2007; Negus and Miller, 2014; Wee et al., 
2005). Furthermore, compounds that produce locomotor increases are likely to be reinforcing 




(Wise and Bozarth, 1987). Therefore, given the preference for DAT-mediated release and motor 
stimulatory effects of 5-IT, it is likely that this drug has high abuse potential. On the other hand, 
the slow onset of in vivo effects for 5-IT may serve to diminish its abuse potential to some 
extent. Previous research in humans and monkeys has shown that a rapid rate of stimulant drug 
delivery is associated with greater reinforcing effects (Abreu et al., 2001; Nelson et al., 2006; 
Woolverton and Wang, 2004). The onset of stimulant effects is reportedly the most pleasurable 
aspect of the drug-taking experience, and a short duration of action allows for more opportunities 
to self-administer, and consequently re-experience the onset of effects (Fischman, 1989). Peak 
locomotor effects of 5-IT did not occur until approximately 80 min post-injection, which is 
considerably longer than that for MDMA, methamphetamine, BZP, and synthetic cathinones 
with releasing properties (Marusich et al., 2012, 2014; Yarosh et al., 2007). Thus, 5-IT may serve 
as an interesting pharmacological tool for investigating the role of pharmacokinetics in animal 
models of drug reinforcement due to its unique time course. 
In contrast with the neurochemical profile of 5-IT, the preference for SERT-mediated 
release exhibited by 6-IT may dampen dopaminergic effects of the drug. For mixed 5-HT/DA 
releasers, previous research has found that 5-HT plays a key role in reducing typical DA-
mediated behaviors such as locomotor stimulation and self-administration (Baumann et al., 2011; 
Rothman et al., 2007; Rothman and Baumann, 2006; Wee et al., 2005). This is consistent with 
the ability of 6-IT to decrease intracranial self-stimulation in rats, and its failure to substitute for 
cocaine in drug discrimination in monkeys (Banks et al., 2014). Evidence suggests that activation 
of 5-HT2C receptors are responsible for the inhibitory actions of 5-HT on DA-mediated behaviors 




(Filip et al., 2010; Howell and Cunningham, 2015), and it is feasible that 6-IT may have direct 
actions at specific 5-HT receptor subtypes in addition to its 5-HT releasing activity. Overall, 
results of the present study combined with those of previous studies indicate that 6-IT may have 
low abuse liability, but enhanced risk for adverse effects. 
A noteworthy finding of the present study is that small structural changes in a drug 
molecule can greatly impact transporter activity. Previous studies on synthetic stimulants have 
found similar results. Repositioning of the 3,4-methylenedioxy group in MDMA to create 2,3-
methylenedioxymethamphetamine (2,3-MDMA) substantially decreases 5-HT uptake while NET 
uptake remains relatively constant (Montgomery et al., 2007). Similarly, a shift in the position of 
the flouro group in 3-fluoromethcathinone to create 4-fluoromethcathinone greatly diminishes 
DAT inhibition (Simmler et al., 2013, 2014). These combined results highlight the importance of 
including isomer identification in toxicological analyses. As the market for new psychoactive 
substances continues to evolve, it is likely that structural isomers of currently available 
compounds will appear in the street drug marketplace as a means to evade regulatory control. 
Including new potential isomers in toxicology screens will allow more rapid identification of 
novel compounds.  One caveat of the results of the present study is that the in vitro release assays 
were conducted in rat brain synaptosomes, whereas the in vivo assays were conducted with mice. 
Mice were chosen for in vivo testing because the quantity of the test compounds was not 
sufficient for testing in rats. The differences in brain circuitry between mice and rats could 
complicate the interpretation of these data. 




A number of drug tablets confiscated by European authorities have been found to contain 
5-IT, and these tablets resemble those being sold as “ecstasy” in the street drug marketplace. 
Users who take such tablets may be exposed to MDMA, various ring-substituted cathinones, 
and/or 5-IT, among other compounds (EMCDDA, 2014). While it is difficult to postulate the 
health effects of these compounds when administered alone or in combination, 
methamphetamine and cocaine taken in combination with MDMA increase the risk of acute 5-
HT toxidrome (i.e., 5-HT syndrome), a condition in which high levels of 5-HT accumulate in the 
brain causing symptoms ranging from mild shivering and diarrhea to severe muscle rigidity, 
fever, seizures, and death (Boyer and Shannon, 2005; Silins et al., 2007). Importantly, the ability 
of 5-IT to simultaneously release monoamines and inhibit MAO A will exacerbate the 
serotonergic effects of co-administered drugs, especially when administered at high doses. 
Therefore, 5-IT taken in combination with MDMA or other serotonergic compounds may lead to 
significant risk of toxicity. 
5.0 Conclusion 
5-IT and 6-IT are potent monoamine releasers which produce a variety of adverse effects 
in an FOB, and 5-IT is also a locomotor stimulant. 5-IT and 6-IT are structurally very similar, yet 
their transporter releasing activities at DAT and SERT are the opposite (i.e., 5-IT is DAT-
preferring while 6-IT is SERT-preferring), indicating that subtle differences in chemical structure 
can have profound effects on biological activity. Thus, the prospect of inferring pharmacology 
from drug structure is a complicated endeavor. The potent monoamine-releasing actions of 5-IT, 
coupled with its known inhibition of MAO A (Herraiz and Brandt, 2014), could underlie its 




dangerous effects when administered alone, and in combination with other monoaminergic drugs 
or medications. Consequently, 5-IT and related compounds may pose substantial risk for abuse 
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Table 1. Effects of amphetamine, MDMA, 5-IT and 6-IT on the release of [3H]MPP+ from DAT 
and NET, and [3H]5-HT from SERT in rat brain synaptosomes. Data are expressed as nM 
concentrations (mean±SD) for n=3 experiments performed in triplicate. 
Test Drug 
[3H]MPP+ release, 
EC50 at DAT 
nM 
[3H]MPP+ release, 
EC50 at NET 
nM 
[3H]5-HT release, 





Amphetamineb   5.8±0.4 6.6±0.7 698±71 120 







12.9±1.5 13.3±1.8  104.8±18.2 8 
6-IT 164.0±15.2 25.6±4.2  19.9±1.6 0.1 
aDAT/SERT ratio was determined by [DAT EC50]-1/ [SERT EC50]-1 such that higher numerical 
value equals greater DAT selectivity 
bAmphetamine data from Baumann et al. (2013b) 
 
 




 Table 2. Effects of MDMA, 5-IT, 6-IT, and methamphetamine (METH) in the FOB. Doses 
(mg/kg) that produced a significant difference from vehicle are shown in columns with the 
corresponding average percent of vehicle shown in parenthesis. The corrected alpha level for 
each domain is noted in parenthesis in the first column. For comparison purposes, doses at which 
beam breaks were significantly increased during the second 10-min bin of the locomotor activity 
sessions are also shown. Only behaviors that were significantly affected by at least one drug are 
included. 
Dependent variable MDMA 5-IT 6-IT METHa 




CNS Activity (α=0.0125)     
Exploration 10.0 (238) 30.0 (300) 30.0 (157) 5.6 (179)  




CNS Excitability (α=0.0056)     








Stereotyped Head Weaving 10.0 (250) 30.0 (275) 
10.0 (142) 








Autonomic Effects (α=0.025)     
Piloerection 3.0 (150) 30.0 (220) 3.0 (160) 5.6 (174) * 
Salivation 30.0 (225)   10.0 (238) 
Muscle tone/Equilibrium (α=0.0125)     




Flattened Body Posture 10.0 (156) 30.0 (178)    
Forepaw Treading 30.0 (213) 10.0 (180)  * 
aMethamphetamine data from Marusich et al. (2012). * Forepaw treading and piloerection 
were not measured in the previous study. 
 






Figure 1. Chemical structures of AMT, 5-IT, 6-IT, and MDMA. 
 
Figure 2. Effects of test drugs on release of [3H]MPP+ via DAT and NET, and [3H]5-HT via 
SERT. Data are mean±SD expressed as a % of maximal release response for n=3 experiments 
performed in triplicate. 
 
Figure 3. Effects of test drugs on cumulative locomotor activity during 90 min sessions, plotted 
as a function of dose. * represents doses that produced significant increases in beam breaks 
compared to vehicle. SV stands for saline vehicle and TV stands for tween vehicle. 
 
Figure 4. Time course of locomotor activity, plotted as a function of 10 min bins. Values 
represent mean±SEM expressed as number of beam breaks for each dose (n=8 per dose). * 
indicates significant increases in beam breaks compared to vehicle at the same time point. # 
represents significant attenuation of the effect of the dose compared to its first 10 min bin. The 
top panel shows data for MDMA, middle panel shows data for 5-IT, and lower panel shows data 
for 6-IT. For 6-IT, # on the x axis indicates significant attenuation compared to the first 10 min 
bin for 1.0-5.6 mg/kg, and $ indicates significant attenuation compared to the first 10 min bin for 
10.0 mg/kg. 
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